뇌혈관질환의 항혈전제 치료에 있어서 약물유전학

키워드

참고문헌 (26)

1. Daly AK, "Pharmacogenetics and human genetic polymorphisms", Bio-chem J, 429, pp.435~449 (2010)
2. Mega JL, "Reduced-function CYP2C19 ge-notype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis", JAMA, 304, pp.1821~1830 (2010)
3. Mega JL, "Cytoch-rome p-450 polymorphisms and response to clopidogrel", N Engl J Med, 360, pp.354~362 (2009)
4. Simon T, "French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events", N Engl J Med, 360, pp.363~375 (2009)
5. Collet JP, "Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study", Lancet, 373, pp.309~317 (2009)
6. Shuldiner AR, "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy", JAMA, 302, pp.849~857 (2009)
7. International Warfarin Pharmacogenetics Consortium, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)
8. Marín F, "Pharmacogenetics in cardiovascular antithrombotic th-erapy", J Am Coll Cardiol, 54, pp.1041~1057 (2009)
9. James AH, "Factors affecting the maintenance dose of warfarin", J Clin Pathol, 45, pp.704~706 (1992)
10. Thacker SM, "Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes", J Thromb Haemost, 6, pp.1445~1449 (2008)
11. Rieder MJ, "Effect of VKO-RC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
12. Limdi NA, "International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups", Blood, 115, pp.3827~3834 (2010)
13. Yasar U, "Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population", Biochem Biophys Res Commun, 254, pp.628~631 (1999)
14. Linder MW, "Warfarin dose adjustments based on CYP2C9 genetic polymorphisms", J Thromb Thrombolysis, 14, pp.227~232 (2002)
15. Taube J, "Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment", Blood, 96, pp.1816~1819 (2000)
16. Paré G, "Effects of CYP2C19 genotype on outcomes of clopidogrel treatment", N Engl J Med, 363, pp.1704~1714 (2010)
17. Holmes DR Jr, "ACCF", AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons, 2010, pp.56, 321~341
18. Wallentin L, "PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 361, pp.1045~1057 (2009)
19. Wallentin L, "PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial", Lancet, 376, pp.1320~1328 (2010)
20. Mega JL, "Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis", Lancet, 376, pp.1312~1319 (2010)
21. Wiviott SD, "TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 357, pp.2001~2015 (2007)
22. Shuldiner AR, "Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy", JAMA, 302, pp.849~857 (2009)
23. Gremmel T, "Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition", Heart, 96, pp.186~189 (2010)
24. Norgard NB, "Drug-drug interaction between clopidogrel and the proton pump inhibitors", Ann Pharmacother, 43, pp.1266~1274 (2009)
25. Neuvonen PJ, "Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance", Clin Pharmacol Ther, 80, pp.565~581 (2006)
26. Lim E, "Dose-related efficacy of aspirin after coronary surgery in patients With Pl(A2) polymorphism (NC T00262275)", Ann Thorac Surg, 83, pp.134~138 (2007)

관련 논문AI추천